Yabao adheres to the development direction of modernizing the production of traditional Chinese medicine as the main body, with chemical drugs and biological drugs as the two wings. It has continuously increased its efforts in technological transformation and established a corporate technology center in the provincial capital Taiyuan. A modernized research center for traditional Chinese medicine was established. At the same time, the company continues to carry out technological transformation and has completed the transformation of GMP for solid preparations, small-volume injections, APIs, patches, ointments, supercritical CO2 extraction of traditional Chinese medicine, warehousing, and environment, and has taken the lead in passing GMP certification in the country. In recent years, Yabao has relied on its strong technical advantages to vigorously develop traditional Chinese medicine products with unique characteristics and advantages, forming a strong position in the treatment of cardiovascular and cerebrovascular diseases, and becoming a representative large-scale traditional Chinese medicine manufacturing enterprise in China.
Yabao focuses on building a developed marketing network, establishing four sales teams for general drugs, agents, OTC and new drugs, reforming the marketing system, constantly expanding market share, and sales outlets throughout the country. The company's products such as troxerutin tablets, nimodipine tablets and compound reserpine tablets have achieved integrated production from raw materials to tablets and injections, and its annual production and sales rank first in the country. Ding Guier's umbilical patch (formerly Baby Yi Tie Ling) is a patented brand-name product exclusively produced in China, with annual production and sales of 100 million patches, and sales revenue in 2004 reaching 125 million yuan.
Yabao continues to increase its efforts in research and development of new products and attaches great importance to the protection of intellectual property rights. It has successively obtained 21 national new drug certificates and production approval documents and 35 production approval documents for generic drugs. A large number of products such as Ding Guier umbilical patch, anti-swelling and analgesic patch, safflower injection, Guanxinning injection, azithromycin injection, Zhenju antihypertensive tablets, etc. have shown strong competitiveness in the market. In recent years, Yabao has applied for 45 patents to the State Intellectual Property Office and obtained 3 invention patent certificates and 16 design patent certificates for Baobao Yitieling, Yantongxiaopie and Ginkgo Leaf Sustained Release Tablets. Declared 112 trademarks to the state, received 24 certificates, and obtained 105 product barcodes. Yabao trademark was rated as a famous trademark in Shanxi Province.
After Yabao’s stock was listed, the company decided to invest 500 million yuan and 300 million yuan to build modern industrial parks in Fenglingdu Provincial Economic Development Zone and Taiyuan National Economic Development Zone respectively. At present, the construction of the Fenglingdu Yabao Industrial Park with an initial investment of more than 200 million yuan and an area of ??400 acres and the Taiyuan Yabao Xinlong Industrial Park with an investment of more than 100 million yuan and an area of ??360 acres have been completed, and both have passed GMP certification. Officially put into operation. After the two industrial parks are put into operation, Yabao will leap to a new stage of development. After more than 30 years of accumulation of pharmaceutical production technology and the introduction of advanced pharmaceutical production technology, the company has mastered technologies such as dynamic extraction of traditional Chinese medicine, supercritical CO2 extraction, macroporous adsorption resin, membrane separation, ultrafine grinding, microwave low-temperature freeze-drying, and fingerprint mapping. .
In the field of preparations, we have mastered technologies such as transdermal absorption, enteric coating, solid dispersion, traditional Chinese medicine injection, and sustained and controlled release.
Quality Assurance
All dosage form product production lines and all varieties of raw materials of the group company have passed the national GMP certification. Each company has established a strict quality assurance system. Drugs are purchased from raw and auxiliary materials. From the moment the finished product leaves the factory, it is always under strict control. Internal control quality standards higher than national standards are formulated for each product, and operating specifications are formulated in accordance with GMP. The quality inspection centers of each company are equipped with internationally advanced testing equipment and instruments. .
National Enterprise Technology Center
Yabao Pharmaceutical Group Enterprise Technology Center was established in 1998 and was recognized as a provincial enterprise technology center by the Shanxi Provincial People's Government in 1999.
On September 26, 2008, after joint approval by five units: the National Development and Reform Commission, the Ministry of Science and Technology, the Ministry of Finance, the General Administration of Customs, and the State Administration of Taxation,
Yabao Pharmaceutical Group Co., Ltd. The technology center is a nationally recognized enterprise technology center and one of the fifteen batches of enterprise technology centers that enjoy preferential policies.